Efficacy of Folfiri in a Colorectal Cancer Subtype Challenged by CNIO Scientists

by Kathy Jones on  November 8, 2014 at 3:38 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

New research has questioned the use of the current classification system for colorectal cancer, which is based on genetic expression profiles, to predict drug responses to FOLFIRI.
 Efficacy of Folfiri in a Colorectal Cancer Subtype Challenged by CNIO Scientists
Efficacy of Folfiri in a Colorectal Cancer Subtype Challenged by CNIO Scientists

This question has been raised by a team from the Spanish National Cancer Research Centre (CNIO), formed by members from the Gastrointestinal Cancer Clinical Research Unit and the Structural Computational Biology Group. The study, published this week in the journal Nature Medicine, will assist oncologists in making better-informed decisions regarding how to treat their colorectal cancer patients in the clinic.

Conclusions from the analysis, led by Manuel Hidalgo, Director of the Clinical Research Programme at CNIO, are in response to previous work published in the same journal in March, 2014 (Sadanandam et al). By means of analysing gene expression profiles, Sadanandam's team designed a classification for colon cancer based on five subtypes, associating one of them, the stemlike subtype, with a better drug response to FOLFIRI; the standard treatment for this tumour type. Specifically, in a 21-patient group, 7 were classified as this subtype, 5 of whom (70%) exhibited a positive response to FOLFIRI. The authors of this article therefore concluded that the classification based on gene expression profiles is directly related to the drug response.

To confirm their conclusion, CNIO researchers, following their protocol, classified 10 patients who had previously been treated at the clinic with this therapy. Three of these patients belonged to the stemlike subtype but none of them responded to treatment with FOLFIRI. Patients belonging to the other subtypes, on the other hand, showed a response to the treatment.

"We have analysed the data from the original work and we see that it is not statistically significant, even when we increase the sample size to ours. The number of patients included in the original study is insufficient to establish a positive correlation between classification of the tumour based on gene expression profiles and sensitivity to FOLFIRI," warns researcher Raquel Martínez, the article's first author.

"Genetic classification of tumours is key to enhancing our understanding of cancer mechanisms and to make personalised therapeutic decisions," explains Hidalgo. "In this case, however, the data must be confirmed by further research studies to keep an erroneous correlation from leading doctors to prescribe inadequate treatments in the clinic."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Cancer and Homeopathy Colo-rectal cancer - Management Colorectal Cancer Cancer Facts Cancer Tattoos A Body Art Amyotrophic Lateral Sclerosis (ALS) Colon Polyps Colorectal Cancer Screening Colorectal Cancer Screening with Colonoscopy 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive